Crossmark

Cost-effectiveness and budget impact analysis of lisdexamfetamine versus methylphenidate for patients under 18 with attention-deficit/hyperactivity disorder in Iran

Crossref DOI link: https://doi.org/10.1186/s13034-023-00664-1

Published Online: 2023-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tajik, Amirmohammad

Nikfar, Shekoufeh

Elyasi, Sepideh

Rajabi, Omid

Varmaghani, Mehdi https://orcid.org/0000-0001-6249-821X
License Information

Text and Data Mining valid from 2023-10-10

Version of Record valid from 2023-10-10
More Information

Article History

Received: 4 June 2023

Accepted: 29 September 2023

First Online: 10 October 2023

Declarations

:

: Ethical approval was not required as this study's data were neither confidential nor commercially sensitive. However, the study has been approved by the Ethics Committee of Mashhad University of Medical Sciences with the code of IR.MUMS.REC.1398.085. Relevant guidelines and regulations are carried out for all methods. Furthermore, informed consent was obtained from all subjects.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below